Cultural advice

The Australian National University acknowledges, celebrates and pays our respects to the Ngunnawal and Ngambri people of the Canberra region and to all First Nations Australians on whose traditional lands we meet and work, and whose cultures are among the oldest continuing cultures in human history.

Aboriginal and Torres Strait Islander peoples are advised that ANU Library collections may include images, names, voices, and other representations of deceased persons.

Material in the collection may contain terms, language or views that reflect the period in which the item was created and may be considered inappropriate today.

PCSK9 inhibitors - clinical applications

Simple item page
dc.contributor.authorSchmidli, Robert
dc.date.accessioned2018-08-29T02:22:27Z
dc.date.issued2016-10
dc.description.abstractThe enzyme PCSK9 has an important role in regulating low-density lipoprotein (LDL) receptors and concentrations of LDL cholesterol. Inhibiting this enzyme could therefore reduce the incidence of ischaemic heart disease. The monoclonal antibodies alirocumab, evolocumab and bococizumab are directed against PCSK9 and inhibit its activity. Phase II trials have shown alirocumab and evolocumab to be effective at lowering LDL cholesterol. Preliminary results of these phase II trials show potential benefits in ischaemic heart disease. Reports of adverse effects, including muscular symptoms and neurocognitive changes, were low. Large phase III cardiovascular outcome trials of these monoclonal antibodies will determine their safety and efficacy. These drugs may have a role in the management of patients at very high risk of cardiovascular events such as those with familial hypercholesterolaemia.en_AU
dc.format3 pagesen_AU
dc.format.mimetypeapplication/pdfen_AU
dc.identifier.issn0312-8008en_AU
dc.identifier.urihttp://hdl.handle.net/1885/146698
dc.publisherNPS MedicineWiseen_AU
dc.rights© National Prescribing Service Ltd. Reproduced with permission. Visit www.nps.org.au. https://www.nps.org.au/copyright (Journal publisher website as of 29/8/2018).en_AU
dc.sourceAustralian prescriberen_AU
dc.source.urihttps://www.nps.org.au/australian-prescriber/articles/pcsk9-inhibitors-clinical-applicationsen_AU
dc.subjectLDL cholesterolen_AU
dc.subjectalirocumaben_AU
dc.subjectbococizumaben_AU
dc.subjectevolocumaben_AU
dc.subjectischaemic heart diseaseen_AU
dc.subjectproprotein convertase subtilisin/kexin type 9en_AU
dc.titlePCSK9 inhibitors - clinical applicationsen_AU
dc.typeJournal articleen_AU
dcterms.accessRightsOpen Accessen_AU
local.bibliographicCitation.issue5en_AU
local.bibliographicCitation.lastpage170en_AU
local.bibliographicCitation.startpage168en_AU
local.contributor.affiliationSchmidli, Robert, ANU Medical School, CHM ANU Medical School, The Australian National Universityen_AU
local.contributor.authoruidu9613542en_AU
local.description.embargo2037-12-31
local.identifier.citationvolume39en_AU
local.identifier.doi10.18773/austprescr.2016.061en_AU
local.identifier.essn1839-3942en_AU
local.publisher.urlhttps://www.nps.org.au/australian-prescriberen_AU
local.type.statusPublished Versionen_AU

Downloads

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
01 Schmidli R PCSK9 inhibitors clinical 2016.pdf
Size:
200.1 KB
Format:
Adobe Portable Document Format
Description:
Download

License bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
884 B
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

ANU Research Publications

DSpace software copyright © 2002-2026 LYRASIS